
Topic
Oncology
HER2-targeted therapy, tumor-type access, buy-and-bill reimbursement, oncology biosimilars, and cancer drug coverage.

Evidence· June 16, 2026 · 12 min read
By Ran Chen#PD-1#Real-World Evidence#Label Warnings

Manufacturing· June 14, 2026 · 11 min read
The oncology injectable shortage, in data: carboplatin and 18 chemo molecules

Deals· June 12, 2026 · 7 min read
GSK pays $10.6B for Nuvalent: zidesamtinib PDUFA Sept 2026, two NSCLC franchises
By Ran Chen#M&A#Oncology#FDA Approval

Pricing & Access· June 10, 2026 · 10 min read
Bispecific antibody access landscape for myeloma and lymphoma

Pricing & Access· June 10, 2026 · 9 min read
CAR-T cell therapy access landscape: seven products in 2026
By Ran Chen#CAR-T#Oncology#Prior Authorization

Pricing & Access· June 10, 2026 · 10 min read
PD-1/PD-L1 checkpoint inhibitor access landscape in 2026

Approvals· June 7, 2026 · 8 min read
Imfinzi + BCG for NMIBC access guide: FDA approval, coding, and buy-and-bill
By Ran Chen#Oncology#PD-L1#Prior Authorization

Pipeline· June 2, 2026 · 10 min read
Orca-T allogeneic cell therapy PDUFA preview: access implications for AML, ALL, and MDS
By Ran Chen#PDUFA Date#FDA Approval#Hematology

Pipeline· June 1, 2026 · 10 min read
Enhertu early-stage breast cancer: neoadjuvant and adjuvant PA workflow
By Ran Chen#Oncology#FDA Approval#Prior Authorization

Pricing & Access· May 31, 2026 · 15 min read
Biomarker documentation mismatch in oncology prior authorization
By Ran Chen#Oncology#Prior Authorization#Payer Policy